Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

NCT03811886 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No accruals

Conditions

Pulmonary Metastatic Osteosarcoma (pOS)

Interventions

DRUG: Natalizumab

Sponsor

Case Comprehensive Cancer Center